Clinical Trial Update: A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of intravenous QEQ278 in patients with advanced solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma

Drugs mentioned

• QEQ278

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell | Phase 1 | Status: TERMINATED